Download PDF
Fortschr Neurol Psychiatr 2001; 69(7): 310-321
DOI: 10.1055/s-2001-15305
ORIGINALARBEIT
© Georg Thieme Verlag Stuttgart · New York

Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung

Symptom-Focussed Pharmacotherapy in Borderline Personality DisorderC. Schmahl, M. Bohus
  • Abteilung für Psychiatrie und Psychotherapie mit Poliklinik, Universitätsklinik für Psychiatrie und Psychosomatik, Freiburg (Ärztl. Direktor: Prof. Dr. M. Berger)
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

Zusammenfassung:

Die Borderline-Persönlichkeitsstörung (BPS) gilt als schwerwiegendes psychiatrisches Störungsbild mit oft sehr heterogener Symptomatik. Obwohl psychotherapeutische Behandlungsverfahren derzeit im Zentrum der Interventionsmöglichkeiten stehen, erfordern schwerwiegende psychopathologische Symptome wie unkontrollierbare Impulsivität, depressive, dissoziative oder psychotische Symptomatik häufig den Einsatz von Psychopharmaka. Herkömmliche Übersichtsarbeiten zur Pharmakotherapie der BPS gliederten sich in der Regel nach Substanzgruppen. In dieser Arbeit wird die Literatur nach den klinisch relevanten Symptomgruppen depressive Symptomatik, Störungen der Affektregulation, Fremdaggressivität, Impulsivität, dissoziative Symptomatik, Selbstverletzungen, Suizidalität, psychotische und pseudopsychotische Symptomatik, Angst, Zwang und Schlafstörungen gegliedert dargestellt. Diese kritische Übersicht würdigt die Relevanz der Studienergebnisse anhand der jeweiligen statistischen Signifikanz. Im Anschluss daran werden aus der Datenlage abgeleitete Therapieempfehlungen zur Pharmakotherapie der Borderline-Persönlichkeitsstörung gegeben: So sollten etwa komorbide depressive Episoden möglichst mit einem Serotonin-Wiederaufnahmehemmer behandelt werden. Auch bei impulsivem und aggressivem Verhalten konnte die Wirksamkeit von Serotonin-Wiederaufnahmehemmern nachgewiesen werden. Bei intermittierender psychotischer Symptomatik sollte auf ein atypisches Neuroleptikum zurückgegriffen werden. Die Behandlung mit Benzodiazepinen ist als obsolet anzusehen.

Symptom-Focussed Pharmacotherapy in Borderline Personality Disorder:

Borderline Personality Disorder (BPD) is a common and serious psychiatric illness. Psychopathological symptoms often are heterogenous and difficult to influence. Psychotherapy stands in the core of treatment efforts. However, during the treatment of these patients often situations occur that make the use of drug treatment necessary. Symptoms such as depression, impulsivity, or dissociation can be difficult to deal with in this population. There appears to be no treatment of choice for the disorder as a whole.

Reviews so far have organized the literature by groups of pharmacological agents. In this review we give an overview over psychopathological symptoms in BPD, i.e. depression, affective dysregulation, aggression, impulsivity, dissociation, self-injuries, suicidality, psychotic symptoms, anxiety, obsessions and compulsions, and sleep disturbance. Effectivity of different drugs in influencing these symptoms is presented and significances of findings are used to assess the relevance of these findings. We conclude that certain symptoms such as depression or impulsivity can be successfully treated. Serotonin reuptake inhibitors play a decisive role in pharmacological treatment of Borderline Personality Disorder. Finally, recommendations for effective drug treatment of BPD symptoms are presented. Comorbid depression should be treated with Selective Serotonin Reuptake Inhibitors. These substances could also be shown to be effective in the treatment of impulsive and aggressive behavior. Intermittent psychotic symptoms are a target for atypical neuroleptics. Benzodiazepines are no longer viewed to be useful in the treatment of BPD.

Literatur

  • 1 Weissman M M. The epidemiology of personality disorders: A 1990 update.  J Personality Disorders. 1993;  7 (suppl spring) 44
    PubMedGoogle Scholar
  • 2 Widiger T A, Frances A J. Epidemiology, diagnosis and comorbidity of borderline personality disorder. In: Tasman A, Hales RE, Frances AJ (Hrsg) Washington, DC: American Psychiatric Press (review of psychiatry series) 1989: 8-24
    Google Scholar
  • 3 Koerner K, Dimeff L. Further Data on Dialectical Behavior Therapy.  Clinical Psychology Science and Practice. 2000;  7 104
    CrossrefPubMedGoogle Scholar
  • 4 Bohus M, Berger M. Die Dialektisch-Behaviorale Psychotherapie nach M.  Linehan.. Nervenarzt. 1996;  67 911-923
    CrossrefPubMedGoogle Scholar
  • 5 Vilkin M I. Comparative chemotherapeutic trial in treatment of chronic borderline patients.  Am J Psychiatry. 1964;  120 1004
    PubMedGoogle Scholar
  • 6 Klein D F. Psychiatric diagnosis and a typology of clinical drug effects.  Psychopharmacology. 1968;  13 359-386
    PubMedGoogle Scholar
  • 7 Gunderson J G. Pharmacotherapy for patients with borderline personality disorder.  Arch Gen Psychiat. 1986;  43 698-700
    PubMedGoogle Scholar
  • 8 Soloff P H. Is there any drug treatment of choice for the borderline personality disorder?.  Arch Gen Psychiat. 1986;  43 698
    PubMedGoogle Scholar
  • 9 Zanarini M C, Gunderson J G, Frankenburg F R, Chauncey D L. The Revised Diagnostic Interview for Borderlines: discriminating borderline personality disorder from other Axis II disorders.  J Personality Dis. 1989;  3 10-18
    PubMedGoogle Scholar
  • 10 Morey L C. Personality Assessment Inventory (PAI). Professional Manual Odessa, FL: Psychological Assessment Resources 1991
    Google Scholar
  • 11 Zimmermann M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder.  Compr Psychiatry. 1999;  40 245-252
    CrossrefPubMedGoogle Scholar
  • 12 Zanarini M C, Frances R, Frankenburg M D, Dubo E, Sickel M, Trikha A, Levin A, Reynolds V. Axis I comorbidity of borderline personality disorder.  Am J Psychiatry. 1998;  155 1733-1739
    Google Scholar
  • 13 Skodol A E, Oldham J M, Gallaher P E. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders.  Am J Psychiatry. 1999;  156 733-738
    PubMedGoogle Scholar
  • 14 Westen D, Moses M J, Silk K R, Lohr N E, Cohen R, Segal H. Quality of depressive experience in borderline personality disorder and major depression: when depression is not just depression.  J Personal Dis. 1992;  6 382-393
    PubMedGoogle Scholar
  • 15 Soloff P H. Lynch KG. Kelly TM. Malone KM. Mann JJ. Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study.  Am J Psychiatry. 2000;  157 601-608
    CrossrefPubMedGoogle Scholar
  • 16 Markovitz P J. Pharmacotherapy of impulsivity, aggression and related disorders. In: Stein D, Hollander E (Hrsg). Impulsive Aggression und Disorders of Impulse Control Sussex, England: J. Wiley 1995: 263-287
    Google Scholar
  • 17 Links P S, Steiner M, Boiago I, Irwin D. Lithium therapy for borderline patients: preliminary findings.  J Personality Dis. 1990;  4 173-181
    PubMedGoogle Scholar
  • 18 Markovitz P J, Calabrese J R, Schulz S C, Meltzer H Y. Fluoxetine in the treatment of borderline and schizotypal personality disorder.  Am J Psychiatry. 1991;  148 1064-1067
    PubMedGoogle Scholar
  • 19 Cornelius J R, Soloff P H, Perel J M, Ulrich R F. Fluoxetine trial in borderline personality disorder.  Psychopharmacol Bull. 1990;  26 151-154
    PubMedGoogle Scholar
  • 20 Silva H, Jerez S, Paredes A. et al . Fluoxetina en el tratamiento de los tratornos limite de personalidad (Fluoxetine in the treatment of borderline personality disorder).  Actas Luso-Esp Neurol Psiquiatr. 1997;  25 391-395
    PubMedGoogle Scholar
  • 21 Benedetti F, Sforzini L, Colombo C. et al . Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.  J Clin Psychiatry. 1998;  59 103-107
    CrossrefPubMedGoogle Scholar
  • 22 de la Fuente J M, Lotstra F. A trial of carbamazepine in borderline personality disorder.  Eur Neuropsychopharmacol. 1994;  4 479
    CrossrefPubMedGoogle Scholar
  • 23 Stein D J, Simeon D, Frenkel M. et al . An open trial of valproate in borderline personality disorder.  J Clin Psychiat. 1995;  56 506
    PubMedGoogle Scholar
  • 24 Soloff P H, George A, Nathan R S. et al . Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.  Arch Gen Psychiat. 1986;  43 691-697
    PubMedGoogle Scholar
  • 25 Soloff P H, George A, Nathan R S. et al . Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.  J Clin Psychopharmacol. 1989;  9 238-246
    CrossrefPubMedGoogle Scholar
  • 26 Soloff P H, George A, Nathan R S. et al . Paradoxical effects of amitriptyline in borderline patients.  Am J Psychiatry. 1986;  143 1603-1605
    PubMedGoogle Scholar
  • 27 Soloff P H, Cornelius J R, George A, Nathan S, Perel J M, Ulrich R F. Efficacy of phenelzine and haloperidol in borderline personality disorder.  Arch Gen Psychiatry. 1993;  50 377-385
    CrossrefPubMedGoogle Scholar
  • 28 Salzman C, Wolfson A N, Schatzberg A. et al . Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.  J Clin Psychopharmacol. 1995;  15 23-29
    CrossrefPubMedGoogle Scholar
  • 29 Coccaro E F, Kavoussi R J. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.  Arch Gen Psychiatry. 1997;  54 1081-1088
    PubMedGoogle Scholar
  • 30 Herpertz S C, Kunert H J, Schwenger U B, Sass H. Affective responsiveness in borderline personality disorder: A psychophysiological approach.  Am J Psychiatry. 1999;  156 1550-1556
    PubMedGoogle Scholar
  • 31 Rifkin A, Quitkin F, Carillo C, Blumberg A G, Klein D F, Oaks G. Lithium carbonate in emotionally unstable character disorders.  Arch Gen Psychiatry. 1972;  27 519-523
    PubMedGoogle Scholar
  • 32 Torgersen S. Genetics in borderline conditions.  Acta Psychiatr Scand. 1994;  89 (Suppl 379) 19-25
    PubMedGoogle Scholar
  • 33 Silverman J M, Pinkham L, Horvath T B. et al . Affective and impulsive personality disorder traits in the relatives of borderline personality disorder patients.  Am J Psychiatry. 1991;  148 1378-1385
    PubMedGoogle Scholar
  • 34 Chengappa K N, Ebeling T, Kang J S. et al . Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder.  J Clin Psychiatry. 1999;  60 477-484
    PubMedGoogle Scholar
  • 35 Kavoussi R J, Liu J, Coccaro E F. An open trial of sertraline in personality disordered patients with impulsive aggression.  J Clin Psychiatry. 1994;  55 137-141
    PubMedGoogle Scholar
  • 36 Wilcox J A. Divalproex sodium as a treatment for borderline personality disorder.  Ann Clin Psychiatry. 1995;  7 33-37
    PubMedGoogle Scholar
  • 37 Schulz S C, Camlin K L, Berry S A, Jesberger J A. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.  Biol Psychiatry. 1999;  46 1429-1435
    CrossrefPubMedGoogle Scholar
  • 38 Brodsky B S, Malone K M, Ellis S P, Dulit R A, Mann J J. Characteristics of borderline personality disorder associated with suicidal behavior.  Am J Psychiatry. 1997;  154 715-1719
    PubMedGoogle Scholar
  • 39 Pinto O C, Akiskal H S. lamotrigene as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.  J Affective Dis. 1988;  51 333-343
    PubMedGoogle Scholar
  • 40 Zanarini M C, Ruser T, Frankenburg F R, Hennen J. The dissociative experiences of borderline patients.  Compr Psychiatry. 2000;  41 223-227
    CrossrefPubMedGoogle Scholar
  • 41 Bernstein E M, Putnam F W. Development, reliability and validity of a dissociation scale.  J Nerv Ment Dis. 1986;  174 727-735
    CrossrefPubMedGoogle Scholar
  • 42 Zanarini M C, Ruser T, Frankenburger F R, Hennen J, Gunderson J. Risk factors associated with the dissociative experience of borderline patients.  J Nerv Ment Dis. 2000;  188 26-30
    CrossrefPubMedGoogle Scholar
  • 43 Jang K L, Paris J, Zweig-Frank H, Livesley W J. Twin study of dissociative experience.  J Nerv Ment Dis. 1998;  186 345-351
    Google Scholar
  • 44 Schmahl C G, Stiglmayr C E, Böhme R, Bohus M. Behandlung von dissoziativen Symptomen bei Borderline - Persönlichkeitsstörungen mit Naltrexon.  Nervenarzt. 1999;  70 262-264
    CrossrefPubMedGoogle Scholar
  • 45 Bohus M J, Landwehrmeyer G B, Stiglmayr C E, Limberger M F, Böhme E R, Schmahl C G. Naltrexone in the treatment of dissociative symptoms in patients with Borderline Personality Disorder: An open-label trial.  J Clin Psychiatry. 1999;  60 598-603
    Google Scholar
  • 46 Favazza A. Suicide gestures and self-mutilation.  Am J Psychiatry. 1998;  146 408-409
    PubMedGoogle Scholar
  • 47 Kempermann I, Russ M J, Shearin E. Self-injurious behavior and mood regulation.  J Personality Dis. 1997;  11 146-157
    PubMedGoogle Scholar
  • 48 Bohus M, Limberger M, Ebner U, Glocker F X, Schwarz B, Wernz M, Lieb K. Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior.  Psychiatry Res. 2000;  95 251-260
    Google Scholar
  • 49 Bohus M. Borderlinepersönlichkeitsstörungen. In: Margraf J (Hrsg). Lehrbuch der Verhaltenstherapie Band 2, 2. Auflage Heidelberg: Springer 1999: 413-437
    Google Scholar
  • 50 Khousam H R, Donnelly N J. Remission of self-mutilation in a patient with borderline personality during risperidone therapy [letter].  J Nerv Ment Dis. 1997;  195 348-349
    PubMedGoogle Scholar
  • 51 Markovitz P J, Wagner S C. Venlafaxine in the treatment of borderline personality disorder.  Psychopharmacol Bull. 1995;  31 773-777
    PubMedGoogle Scholar
  • 52 Roth A S, Ostroff R B, Hoffman R E. Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial.  J Clin Psychiatry. 1996;  57 233-237
    PubMedGoogle Scholar
  • 53 Frances A, Fyer M R, Clarkin J. Personality and Suicide.  Ann NY Acad Sci. 1986;  487 281-293
    PubMedGoogle Scholar
  • 54 Stone M H, Hurt S, Stone D K. The PI 500: Long-term follow-up of borderline inpatients meeting DSM-III criteria. I. Global outcome.  J Personality Dis. 1987;  1 291-298
    PubMedGoogle Scholar
  • 55 Paris J, Nowlis D, Brown R. Predictors of suicide in borderline personality disorder.  Can J Psychiatry. 1989;  34 8-9
    PubMedGoogle Scholar
  • 56 Soloff P H, Lis J A, Kelly T, Cornelius J, Ulrich R. Risk factors for suicidal behavior in borderline personality disorder.  Am J Psychiatry. 1994;  151 1316-1323
    PubMedGoogle Scholar
  • 57 Silk K R, Lee S, Hill E M, Lohr N. Borderline personality disorder symptoms and severity of sexual abuse.  Am J Psychiatry. 1995;  152 059-1064
    PubMedGoogle Scholar
  • 58 Gunderson J G. Borderline Personality Disorder. Washington, DC: American Psychiatric Press 1984
    Google Scholar
  • 59 Cowdry R W, Pickar D, Davies R. Symptoms and EEG findings in the borderline syndrome.  Int J Psychiatry Med. 1985;  15 201
    PubMedGoogle Scholar
  • 60 Shearer S L, Peters C P, Quaytman M S, Wadman B E. Intent and lethality of suicide attempts among female borderline patients.  Am J Psychiatry. 1988;  145 1424-1427
    PubMedGoogle Scholar
  • 61 Cowdry R W, Gardner D L. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.  Arch Gen Psychiatry. 1988;  45 111-119
    PubMedGoogle Scholar
  • 62 Gardner D L, Cowdry R W. Alprazolam-induced dyscontrol in borderline personality disorder.  Am J Psychiatry. 1985;  142 98
    PubMedGoogle Scholar
  • 63 Zanarini M C, Gunderson J G, Frankenburg F R. Cognitive features of borderline personality disorder.  Am J Psychiatry. 1990;  147 57-63
    CrossrefPubMedGoogle Scholar
  • 64 Rijnders R J, Laman D M, VanDiujn H. Cyproheptadine for Posttraumatic Nightmares.  Am J Psychiatry. 2000;  157 1524-1525
    CrossrefPubMedGoogle Scholar
  • 65 Szigethy E M, Schulz S C. Risperidone in comorbid borderline personality disorder and dysthymia [letter].  J Clin Psychopharmacol. 1997;  17 326-327
    CrossrefPubMedGoogle Scholar
  • 66 Norden M J. Fluoxetine in borderline personality disorder.  Prog Neuropsychopharmacol Biol Psychiatry. 1989;  13 885-893
    CrossrefPubMedGoogle Scholar
  • 67 Frankenburg F R, Zanarini M C. Clozapine treatment of borderline patients: a preliminary study.  Compr Psychiatry. 1993;  34 402
    CrossrefPubMedGoogle Scholar
  • 68 Parsons B, Quitken F M, McGrath P J. et al . Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.  Psychopharmacol Bull. 1989;  25 524-534
    PubMedGoogle Scholar
  • 69 Siever L J, New A S, Kirrane R. et al .New biological research strategies for personality disorders. In: Silk K (Hrsg). Biology of Personality Disorders. Washington, DC: American Psychiatric Press (review of psychiatry series) 1998: 27-61
    Google Scholar
  • 70 Linehan M M, Armstrong H E, Suarez A, Allmon D, Heard H L. Cognitive-behavioral treatment of chronically suicidal borderline patients.  Arch Gen Psychiatry. 1991;  48 1060-1064
    PubMedGoogle Scholar
  • 71 Linehan M M, Heard H L, Armstrong H E. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients.  Arch Gen Psychiatry. 1993;  50 971-974
    PubMedGoogle Scholar
  • 72 Rothenhäusler H B, Kapfhammer H P. Der Verlauf von Borderline-Störungen. Eine Literaturübersicht.  Fortschr Neurol Psychiat. 1999;  67 200-217
    PubMedGoogle Scholar

Dr. med. Christian Schmahl

Universitätsklinik für Psychiatrie und Psychosomatik
Abteilung für Psychiatrie und Psychotherapie mit Poliklinik

Hauptstraße 5

79104 Freiburg

Email: E-mail: christian_schmahl@psyallg.ukl.uni-freiburg.de

      >